Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC008543 | Panoply™ Human LAP3 Knockdown Stable Cell Line | Inquiry |
| CSC-SC008543 | Panoply™ Human LAP3 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT2134 | Human LAP3 Knockout Cell Line-A549 | Inquiry |
| CLOE-0152 | Human LAP3 HEK293 Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD09010Z | Human LAP3 adenoviral particles | Inquiry |
| LV16755L | human LAP3 (NM_015907) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH142103 | shRNA set against Rat Lap3(NM_001011910.1) | Inquiry |
| SHH142139 | shRNA set against Human LAP3(NM_015907.2) | Inquiry |
| SHH328439 | shRNA set against Human LAP3 (NM_015907.2) | Inquiry |
| SHH328443 | shRNA set against Mouse LAP3 (NM_024434.6) | Inquiry |
| SHH328447 | shRNA set against Rat LAP3 (NM_001011910.1) | Inquiry |
| SHW001932 | shRNA set against Chicken LAP3 (NM_001031336) | Inquiry |
| SHW012369 | shRNA set against Danio rerio LAP3 (NM_001114847) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCR300112 | Human LAP3 ORF Clone(NM_015907.2) | Inquiry |
| CDFH010203 | Human LAP3 cDNA Clone(NM_015907.2) | Inquiry |
| CDFH010204 | Human LAP3 cDNA Clone(NM_015907.2) | Inquiry |
| CDFR002340 | Rat Lap3 cDNA Clone(NM_001011910.1) | Inquiry |
| MiUTR1H-05570 | LAP3 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-02958 | LAP3 miRNA 3'UTR clone | Inquiry |
| CDCB158118 | Human LAP3 ORF clone (BC065564) | Inquiry |
| CDCB163407 | Chicken LAP3 ORF Clone (NM_001031336) | Inquiry |
| CDCB173844 | Danio rerio LAP3 ORF Clone (NM_001114847) | Inquiry |
| CDCB189803 | Rabbit LAP3 ORF clone (XM_002709366.2) | Inquiry |
| CDCR007756 | Mouse LAP3 ORF clone(NM_024434.6) | Inquiry |
| CDCR369427 | Rat Lap3 ORF Clone(NM_001011910.1) | Inquiry |
| CDCS414073 | Human LAP3 ORF Clone (BC065564) | Inquiry |
Recent Progress
Leucine aminopeptidase 3 (LAP3), belonging to the M1 family, has been proved to catalyze the hydrolysis of leucine residues. Leucine aminopeptidases are involved in many pathological disorders and regulate cell proliferation, invasion and angiogenesis of tumor. Recent study showed that LAP3 is highly expressed in several malignant tumors and affects tumor angiogenesis. In investigating the clinical significance of LAP3 expression in human gliomas and its biological function in glioma cells, various methods were used to detect the expression levels of LAP3 in 121 glioma tissues. High LAP3 expression was correlated with the grade of malignancy and poor prognosis of glioma patients. In vitro, knockdown of LAP3 by siRNA transfection in glioma cells, cell viability, cell cycle, migration and invasion were determined. The results indicated that increasing LAP3 could promote cell viability, cell cycle, migration and invasion. Knockdown of LAP3 could decrease cell viability, suppress cell proliferation, migration and invasion. These findings uncovered that LAP3 might be a new prognostic factor and be close correlation with glioma cell growth, migration, invasion.
In exploration of the clinical significance and biological function of LAP3 in hepatocellular carcinoma (HCC), researchers demonstrated that LAP3 expression was significantly up-regulated in HCC tissues as well as cells and was closely correlated with lower differentiation, and positive lymph node metastasis, indicating a poor prognosis. Results of the study also revealed that LAP3 promoted HCC cells proliferation by regulating G1/S checkpoint in cell cycle and promoted HCC cells migration. Furthermore, knockdown of LAP3 enhanced the sensitivity of HCC cells to cisplatin, thus facilitating the cell death of HCC cells. Taken together, these findings indicated that up-regulated expression of LAP3 might contribute to the proliferation and metastasis of HCC (Fig.1).
Fig. 1. LAP3 is expressed in HCC tissues and cells. (Tian et al, 2014)
In another study, it was hypothesized that cancer tissue immunogens and antigens capable of inducing specific antibody production in patients are promising targets for development of precision diagnostics and humoral immunotherapies. Researchers thus developed an innovative immuno-proteomic strategy and identified new immunogenic markers of colon cancer. Proteins from cancers and matched normal tissues were selected while 170 serum antibody-reactive proteins were identified. Among these, proteasome subunit alpha type 1 (PSA1), leucine aminopeptidase 3 (LAP3), annexin A3 (ANXA3), and maspin (serpin B5) were reproducibly found in tissues from three patients. Differential expression patterns were confirmed in samples from eight patients with various stages of colon adenocarcinoma and liver metastases. These tumor-resident proteins and their associated serum antibodies may be promising markers for colon cancer screening and early diagnosis. Furthermore, tumor tissue-specific antibodies could potentially be used as immunotherapeutic targets against cancer. More generally, proteomic profiling of cancer-associated immunogens represents a powerful generic method for uncovering the tumor totality of immunogenic tumor-associated proteins.
References: